Fluconazole

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

三唑类抗真菌剂，用于治疗艾滋病口咽部念珠菌病和隐球菌性脑膜炎。

Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. (In Vitro):Fluconazole inhibits 4 species ofAspergillus fumigatus with the IC50s of 23.9-43.5 μg/mL. Fluconazole (0.20 μg/mL) inhibits significantly the mycelial-phase growth and germ tube elongation of C. albicans in a medium supplemented with serum.Fluconazole is a triazole antifungal agent that has been available for the treatment of infections due to Candida, Cryptococcus. The MIC90 is highest for C. krusei (MIC ≥ 64 μg/mL) and C. glabrata (MIC, 32 μg/mL) and is ≤2 μg/mL for C. albicans (0.5 μg/mL), C. parapsilosis (2 μg/mL), C. tropicalis (2 μg/mL), C. lusitaniae (2 μg/mL), and C. kefyr (0.5 μg/mL).Fluconazole (0.1-50.0 μg/mL) damages the fungal cells and reduces their viability.(In Vivo):Fluconazole ( 0, 0.5, 1, 2.5, 5, 7.5, and 10 mg/kg; administered intraperitoneally (i.p.) as a single dose) results in a 50% reduction in fungal densities (ED50) of 4.87 mg/kg in a murine model of systemic candidiasis. Fluconazole exhibits terminal elimination half-life of 2.4 h) following i.p.

Cell Viability Assay Cell Line:C.albicans yeast cells (strain ATCC 26310 and strain TW) Concentration:0.1, 0.5, 5.0, 50.0 μg/mL Incubation Time:24 hours Result:The MICs against both strains were 0.5 μg/mL.

Animal Model:Female NYLAR mice (weight, 18 to 20 g; infected intravenously with C. albicans blastoconidia)Dosage:5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis) Administration:Given i.p. as a single dose Result:T1/2=2.4 h

UK 49858

Microbiology/Virology

Antifection

14-α Demethylase

Infection

——

86386-73-4

306.27

C13H12F2N6O

>98% (HPLC)

Ethanol: 61 mg/mL (199.17 mM); DMSO: 61 mg/mL (199.17 mM)

OC(CN1N=CN=C1)(C2=CC=C(F)C=C2F)CN3N=CN=C3

2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol

(-20℃)

With Ice Pack

≥ 2 years